Xilio Therapeutics, Inc. Stock Price, News & Analysis

Xilio Therapeutics (Nasdaq: XLO) has appointed Akintunde (Tunde) Bello, Ph.D., to its board of directors. Dr. Bello brings over 25 years of oncology drug development experience, particularly in translational medicine and clinical pharmacology. He recently retired as senior vice president at Bristol Myers Squibb, where he led clinical pharmacology and pharmacometrics. His expertise spans complex biologics and immunotherapies, including anti-CTLA-4, PD-1 checkpoint inhibitors, and T cell engagers. The appointment comes as Xilio advances XTX501, its masked PD-1/IL-2 bi-specific program, along with other bi-specific and tri-specific masked T cell engager programs. Dr. Bello previously held leadership roles at Pfizer, overseeing clinical pharmacology for late-stage oncology development programs.

Xilio Therapeutics (XLO) has completed a public offering raising initial gross proceeds of $50.0 million through pre-funded warrants and common stock warrants. The offering was co-led by Coastlands Capital and Frazier Life Sciences, with participation from Gilead Sciences, Logos Capital, Samsara BioCapital, and other investors. The company issued 66,676,000 pre-funded warrants with accompanying Series A, B, and C warrants. If all Series B and C warrants are exercised at $0.75 per share, Xilio could receive up to an additional $100 million by end of 2026, potentially reaching total gross proceeds of $150 million. The company can cancel warrants proportionally to non-dilutive capital received. Proceeds will support product candidate development and general corporate purposes.

Xilio Therapeutics (XLO) has granted stock options to five new employees as part of their employment inducement package. The grants, effective June 1, 2025, include options to purchase 181,300 shares of common stock at an exercise price of $1.07 per share, matching the company's closing price on May 30, 2025. The options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (XLO) has priced a $50.0 million public offering of pre-funded warrants and multiple series of warrants. The offering includes pre-funded warrants to purchase 66,676,000 shares, along with Series A, B, and C warrants, each to purchase the same number of shares. The combined offering price is $0.7499 per unit. The pre-funded warrants have a $0.0001 exercise price, while Series A, B, and C warrants have a $0.75 exercise price with different exercise periods and conditions. If all Series B and C warrants are exercised in cash, the company could receive additional gross proceeds of up to $100.0 million. The proceeds will be used for product candidate development and general corporate purposes. Leerink Partners is serving as the sole bookrunner, with the offering expected to close around June 5, 2025.

Xilio Therapeutics, a clinical-stage biotech company focused on tumor-activated immuno-oncology therapies, has announced a proposed public offering of pre-funded warrants to purchase common stock. The offering includes Series A, B, and C warrants, with all securities being offered by Xilio. The company plans to use the proceeds to advance its product candidate development and for working capital and general corporate purposes. Leerink Partners is serving as the sole bookrunner for the offering. The offering will be made through a shelf registration statement on Form S-3 that was filed with the SEC on March 11, 2025, and declared effective on May 8, 2025. The final terms and completion of the offering are subject to market conditions.

Xilio Therapeutics (XLO) reported promising Phase 2 data for vilastobart combined with atezolizumab in treating metastatic microsatellite stable colorectal cancer (MSS CRC). The trial showed a 26% preliminary objective response rate in patients without liver metastases, with responses lasting up to 37 weeks. Of 44 treated patients (median age 55), 80% had received three or more prior cancer therapies. The drug combination demonstrated a favorable safety profile with only 7% of patients experiencing colitis. Seven partial responses were observed in patients without liver metastases, with six confirmed responses. The treatment showed substantial decreases in tumor biomarkers and improved clinical symptoms. Xilio is now enrolling patients at a higher dose level (150mg Q6W) and plans to report additional data in H1 2026. The company is seeking partnership opportunities to advance the vilastobart program.

Xilio Therapeutics (XLO) reported Q1 2025 financial results and pipeline updates. Key highlights include: promising Phase 2 data for vilastobart (anti-CTLA-4) combined with atezolizumab, showing 27% objective response rate in MSS CRC patients without liver metastases. The company is advancing multiple masked T cell engager programs, with first development candidates expected in H2 2025. Financially, Xilio ended Q1 with $89.1 million in cash, boosted by a $52 million upfront payment from AbbVie collaboration. Q1 revenue was $2.9M, with reduced R&D expenses at $8.3M (vs $10.4M in Q1 2024) and increased G&A expenses at $8.5M (vs $6.1M). Net loss improved to $13.3M from $17.2M year-over-year. Current cash runway extends into Q1 2026.

Xilio Therapeutics (XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to a new employee. The inducement grant includes options to purchase 5,000 shares of common stock at an exercise price of $0.755 per share, equal to the closing price on May 1, 2025. The options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. This grant was made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (Nasdaq: XLO) has announced it will present updated Phase 2 clinical trial data for vilastobart (XTX101) at the 2025 ASCO Annual Meeting. The presentation will focus on the combination therapy of vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC).

The data presentation is scheduled for Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT during the Gastrointestinal Cancer - Colorectal and Anal poster session at the conference in Chicago, Illinois. The abstract ID is 3553 and will be displayed on Poster Board 222.